https://www.purduebio.com

Data Sheet

Product Information

Catalog Number	BP12518
Product Name	TA-02
Description	TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295).
Targets&IC50	p38 MAPK:20 nM
In vitro	TA-02 (5 μM) inhibits the phosphorylation of proteins downstream of p38α MAPK such asMAPKAPK2 and HSP27 during cardiogenesis. TA-02 at 5 μM concentration induces cardiogenesis, but also increases ATF-2 phosphorylation and MEF2C õexpression in contrast to what would be expected with a mechanism dependent on p38α MAPK inhibition.TA-02 induces T/Brachyury whereas SB203580 addition increased MESP1 and T/Brachyury transcripts.TA-02 significantly induces high NKX2-5 expression when applied between days 0-8.TA-02 is found to inhibit multiple targets with similar potency to p38α MAPK, such as p38α, p38β, JNK3, JNK2, CIT, CK1ε, DMPK2, JNK1, DDR1 CK1δ, MEK5, and ERBB2.TA-02 and SB203580 reduce the nuclear TCF/LEF-1 driven transcription of luciferase similar to DKK-1.TA-02 (5 nM-5 μM) inhibits p38 and increases the anti-inflammation effects of BDNF on inflammation in vitro.
Synonyms	TA 02, TA02
CAS No.	1784751-19-4
Chemical Formula	C20H13F2N3
Molecular Weight	333.342

Solubility	DMSO: ≥ 34 mg/mL (83.67 mM)
Storage	Powder: -20°C for 2 years In solvent: -80°C for 1 year
Chemical Structure OR Tested Image	

Purdue Bioscience Inc.

750 50th St, Brooklyn, NY 11220, USA

https://www.purduebio.com

1-877.618.7311

info@purduebio.com

v2 Revision on 12/28/2022